3.68
-0.18 (-4.72%)
| Previous Close | 3.86 |
| Volume | 4,171 |
| Price / Sales | 1.37 |
| Price / Book | 0.560 |
| 52 Weeks Range |
| Operating Margin (TTM) | -991.41% |
| Diluted EPS (TTM) | -33.20 |
| Quarterly Revenue Growth (YOY) | -76.80% |
| Total Debt/Equity (MRQ) | 52.79% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | -57.90 M |
| Levered Free Cash Flow (TTM) | -34.68 M |
| Return on Assets (TTM) | -34.57% |
| Return on Equity (TTM) | -83.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Bolt Biotherapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.83 |
|
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.26% |
| % Held by Institutions | 46.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Board Of Trustees Of The Leland Stanford Junior University | 30 Jun 2026 | 35,977 |
| Nan Fung Group Holdings Ltd | 30 Jun 2026 | 5,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |